Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BK1901 as a Booster in Japanese Children
jRCT2031200412Phase 2Completed
- Sponsor
- Research Foundation for Microbial Diseases of Osaka University
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of BK1901 in pertussis, diphtheria, Tetanus and 1 more, sponsored by Research Foundation for Microbial Diseases of Osaka University. Primary endpoints: Booster response rates to DPT and polio antigens and Safety: adverse events and adverse reactions. Started Mar 2021; status: completed.
02
Drugs
BK1901
03
Conditions
pertussisdiphtheriaTetanuspoliomyelitis
Beyond the preview
Go deeper on jRCT2031200412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200412.